Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)

  • STATUS
    Recruiting
  • End date
    Sep 17, 2026
  • participants needed
    144
  • sponsor
    Institut de cancérologie Strasbourg Europe
Updated on 18 October 2021
cancer
primary cancer
targeted therapy
immunostimulants

Summary

This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.

Description

At the ICANS an EPODIG-G program, consisting in a coordination of supportive care that are existing in the Institute, is proposed to elderly patients with digestive cancer. The purpose of this study is to evaluate the impact of this early multidisciplinary geriatric program (EPODIG-G), when it is initiated before therapeutic treatment.

Details
Condition Ewing's Family Tumors, digestive disorders, gastrointestinal disorders, gastrointestinal tract tumor, digestive system tumor, digestive disease, Neoplasm of unspecified nature of digestive system, gastrointestinal tumors, Gastrointestinal Neoplasm, gastrointestinal diseases, Cancer/Tumors, GASTROINTESTINAL DISORDER, Digestive System Disease, digestive diseases, gastrointestinal tumor, gastrointestinal disease, digestive disorder, Digestive System Neoplasms, Neoplasms, digestive system neoplasm, Gastrointestinal Diseases and Disorders, Cancer, Cancer (Pediatric)
Treatment EPODIG-G program (coordination of supportive care)
Clinical Study IdentifierNCT05066139
SponsorInstitut de cancérologie Strasbourg Europe
Last Modified on18 October 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must be 75 years old
Performance status 0, 1 or 2
Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy
Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible
Estimated life expectancy 3 months
Patients able to speak, read and understand French
Signed informed consent from the patient
Patients must have a social security coverage

Exclusion Criteria

History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine)
History of another treated cancer during the last five years
History of major surgery and/or curative radiation therapy during the last 4 weeks before inclusion
Patients unable to submit to medical follow-up for geographical, social or psychological reasons
Patients placed under guardianship
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note